The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
The country is sixth among the most affected countries by active cases
UCB plans to submit regulatory applications in Q3 2022
Previously, the use of the drug was limited to patients requiring hospitalization
Go-ahead for pivotal clinical trial which is expected to commence by March
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Biocon has reported consolidated financial results for the period ended December 31, 2021
Subscribe To Our Newsletter & Stay Updated
